3.29

2.66% -0.09

After Hours: 3.28 -0.01 -0.30%

Abcellera Biologics Inc (ABCL)

Overview News Price History Option Chain Financials Why ABCL Down? Discussions Forecast

Abcellera Biologics Inc stock is traded at $3.29, with a volume of 2.57M. It is down -2.66% in the last 24 hours and down -0.60% over the past month. AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company have extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.

Previous Close:

$3.38

Open:

$3.41

24h Volume:

2.57M

Relative Volume:

0.83

Market Cap:

$971.76M

Revenue:

$38.03M

Net Income/Loss:

$-146.40M

P/E Ratio:

-6.3269

EPS:

-0.52

Net Cash Flow:

$-121.38M

1W Performance:

+1.86%

1M Performance:

-0.60%

6M Performance:

+15.44%

1Y Performance:

-36.49%

1-Day Range:

$3.26

$3.42

1-Week Range:

$2.955

$3.42

52-Week Range:

$2.335

$5.46

Abcellera Biologics Inc Stock (ABCL) Company Profile

Name

Abcellera Biologics Inc

Sector

Healthcare (1177)

Industry

Biotechnology (679)

Phone

(604) 559-9005

Address

2215 YUKON STREET, VANCOUVER

Employee

586

Twitter

Next Earnings Date

2024-11-18

Latest SEC Filings

ABCL's Discussions on Twitter

Compare ABCL with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ABCL Abcellera Biologics Inc	3.29	971.76M	38.03M	-146.40M	-121.38M	-0.52
VRTX Vertex Pharmaceuticals Inc	481.16	123.91B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	722.07	78.94B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	657.97	39.98B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	278.25	35.89B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	119.94	28.75B	3.30B	-501.07M	1.03B	-2.1146

Abcellera Biologics Inc Stock (ABCL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-20-24	Downgrade	The Benchmark Company	Buy → Hold
Feb-22-24	Upgrade	The Benchmark Company	Hold → Buy
Dec-05-23	Initiated	KeyBanc Capital Markets	Overweight
Nov-06-23	Downgrade	The Benchmark Company	Buy → Hold
Oct-13-23	Resumed	Piper Sandler	Overweight
Feb-28-23	Initiated	Cowen	Outperform
Dec-15-22	Initiated	Goldman	Buy
Nov-16-22	Initiated	Truist	Buy
Dec-21-21	Initiated	The Benchmark Company	Buy
Nov-19-21	Initiated	Piper Sandler	Overweight
Jan-05-21	Initiated	BMO Capital Markets	Outperform
Jan-05-21	Initiated	Berenberg	Buy
Jan-05-21	Initiated	Credit Suisse	Outperform
Jan-05-21	Initiated	SVB Leerink	Outperform
Jan-05-21	Initiated	Stifel	Buy

View All

Abcellera Biologics Inc Stock (ABCL) Latest News

Feb 01, 2025

AbCellera Biologics (NASDAQ:ABCL) Shares Down 4%Here's Why - MarketBeat

Feb 01, 2025

Jan 28, 2025

AbbVie, AbCellera expand collaboration into T-cell engagers - MSN

Jan 28, 2025

Jan 27, 2025

ABCL (AbCellera Biologics) Shares Outstanding (EOP) : 295.16 Mil (As of Sep. 2024) - GuruFocus.com

Jan 27, 2025

Jan 24, 2025

AbCellera Biologics (NASDAQ:ABCL) Shares Up 18.8%Here's What Happened - MarketBeat

Jan 24, 2025

Jan 22, 2025

AbCellera Biologics (NASDAQ:ABCL) Stock Price Up 18.8%Here's What Happened - MarketBeat

Jan 22, 2025

Abcellera Biologics, other AI health stocks gain as Ellison touts AI's promise - MSN

Jan 22, 2025

Jan 21, 2025